AU2003296802A1 - Prevention and treatment of alzheimer's disease - Google Patents

Prevention and treatment of alzheimer's disease Download PDF

Info

Publication number: AU2003296802A1
Authority: AU; Australia
Prior art keywords: alkyl; disease; application; inhibitors; biliary
Prior art date: 2002-12-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2003296802A

Other languages

English (en)

Inventor

Jesus Benavides

Thierry Canton

Hubert Heuer

Laurent Pradier

Hans-Ludwig Schaefer

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Aventis Pharma SA

Original Assignee

Aventis Pharma SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-12

Filing date

2003-12-10

Publication date

2004-08-10

2003-12-10 Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA

2004-08-10 Publication of AU2003296802A1 publication Critical patent/AU2003296802A1/en

Status Abandoned legal-status Critical Current

Links

208000024827 Alzheimer disease Diseases 0.000 title claims description 33
238000011282 treatment Methods 0.000 title claims description 18
230000002265 prevention Effects 0.000 title claims description 12
239000003112 inhibitor Substances 0.000 claims description 60
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 55
239000003613 bile acid Substances 0.000 claims description 46
150000001875 compounds Chemical class 0.000 claims description 33
235000012000 cholesterol Nutrition 0.000 claims description 16
238000002360 preparation method Methods 0.000 claims description 14
239000003814 drug Substances 0.000 claims description 13
238000000034 method Methods 0.000 claims description 12
229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 10
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
201000010099 disease Diseases 0.000 claims description 9
239000008194 pharmaceutical composition Substances 0.000 claims description 9
150000008163 sugars Chemical class 0.000 claims description 8
235000000346 sugar Nutrition 0.000 claims description 7
102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims description 6
108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims description 6
239000002253 acid Substances 0.000 claims description 6
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
230000015572 biosynthetic process Effects 0.000 claims description 5
230000000149 penetrating effect Effects 0.000 claims description 5
229940121773 Secretase inhibitor Drugs 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 4
125000000217 alkyl group Chemical group 0.000 claims description 4
125000000539 amino acid group Chemical group 0.000 claims description 4
150000002016 disaccharides Chemical class 0.000 claims description 4
230000000871 hypocholesterolemic effect Effects 0.000 claims description 4
238000003786 synthesis reaction Methods 0.000 claims description 4
150000004043 trisaccharides Chemical class 0.000 claims description 4
150000001720 carbohydrates Chemical class 0.000 claims description 3
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims description 3
125000004076 pyridyl group Chemical group 0.000 claims description 3
230000001225 therapeutic effect Effects 0.000 claims description 3
229940127328 Cholesterol Synthesis Inhibitors Drugs 0.000 claims description 2
CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 2
229910052794 bromium Inorganic materials 0.000 claims description 2
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 2
229910052801 chlorine Inorganic materials 0.000 claims description 2
229910052731 fluorine Inorganic materials 0.000 claims description 2
125000001153 fluoro group Chemical group F* 0.000 claims description 2
229910052736 halogen Inorganic materials 0.000 claims description 2
150000002367 halogens Chemical class 0.000 claims description 2
125000001072 heteroaryl group Chemical group 0.000 claims description 2
229910052740 iodine Inorganic materials 0.000 claims description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
239000000047 product Substances 0.000 description 16
108090000765 processed proteins & peptides Proteins 0.000 description 12
FBKFDSUZBVDZIX-FFGDOFBPSA-N (4s)-4-[[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-acetamido-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-2-methylpropanoyl]amino]-3-[4-(phosphonomethyl)phenyl]propanoyl]amino]-3-(6-chloro-1h-indol-3-yl)propanoyl]amino]-5-[[1-[[(2s)-1-amino-4-meth Chemical group C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NC(C)(C)C(=O)N[C@@H](CC=1C=CC(CP(O)(O)=O)=CC=1)C(=O)N[C@@H](CC=1C2=CC=C(Cl)C=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)NC1(CC1)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(C)=O)C1=CC=CC=C1 FBKFDSUZBVDZIX-FFGDOFBPSA-N 0.000 description 10
210000004556 brain Anatomy 0.000 description 10
230000002490 cerebral effect Effects 0.000 description 8
238000011870 unpaired t-test Methods 0.000 description 5
208000037259 Amyloid Plaque Diseases 0.000 description 4
239000000825 pharmaceutical preparation Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
238000011830 transgenic mouse model Methods 0.000 description 4
229940123239 Cholesterol synthesis inhibitor Drugs 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000699660 Mus musculus Species 0.000 description 3
102100022033 Presenilin-1 Human genes 0.000 description 3
239000000969 carrier Substances 0.000 description 3
230000002354 daily effect Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
230000035772 mutation Effects 0.000 description 3
WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 description 2
208000031124 Dementia Alzheimer type Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
208000035150 Hypercholesterolemia Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
108010036933 Presenilin-1 Proteins 0.000 description 2
102100022036 Presenilin-2 Human genes 0.000 description 2
108010036908 Presenilin-2 Proteins 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
230000009471 action Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
238000003556 assay Methods 0.000 description 2
WZSDNEJJUSYNSG-UHFFFAOYSA-N azocan-1-yl-(3,4,5-trimethoxyphenyl)methanone Chemical compound COC1=C(OC)C(OC)=CC(C(=O)N2CCCCCCC2)=C1 WZSDNEJJUSYNSG-UHFFFAOYSA-N 0.000 description 2
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000006735 deficit Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
-1 for example Substances 0.000 description 2
229960000789 guanidine hydrochloride Drugs 0.000 description 2
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
239000000203 mixture Substances 0.000 description 2
150000002772 monosaccharides Chemical class 0.000 description 2
239000006187 pill Substances 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
238000013519 translation Methods 0.000 description 2
MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 description 1
125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
229940126062 Compound A Drugs 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 description 1
RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 description 1
RGHNJXZEOKUKBD-MGCNEYSASA-N D-galactonic acid Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-MGCNEYSASA-N 0.000 description 1
DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
HAIWUXASLYEWLM-UHFFFAOYSA-N D-manno-Heptulose Natural products OCC1OC(O)(CO)C(O)C(O)C1O HAIWUXASLYEWLM-UHFFFAOYSA-N 0.000 description 1
RGHNJXZEOKUKBD-MBMOQRBOSA-N D-mannonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O RGHNJXZEOKUKBD-MBMOQRBOSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010056474 Erythrosis Diseases 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 1
108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
HSNZZMHEPUFJNZ-UHFFFAOYSA-N L-galacto-2-Heptulose Natural products OCC(O)C(O)C(O)C(O)C(=O)CO HSNZZMHEPUFJNZ-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
101800001442 Peptide pr Proteins 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
HAIWUXASLYEWLM-AZEWMMITSA-N Sedoheptulose Natural products OC[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@](O)(CO)O1 HAIWUXASLYEWLM-AZEWMMITSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001299 aldehydes Chemical group 0.000 description 1
IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
150000001320 aldopentoses Chemical class 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003529 anticholesteremic agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
101150031224 app gene Proteins 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
230000030833 cell death Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
238000004040 coloring Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
229960000815 ezetimibe Drugs 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
239000000174 gluconic acid Substances 0.000 description 1
235000012208 gluconic acid Nutrition 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
102000046783 human APP Human genes 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
231100000863 loss of memory Toxicity 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000004898 mitochondrial function Effects 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000002981 neuropathic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
230000036542 oxidative stress Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
150000002972 pentoses Chemical class 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
HSNZZMHEPUFJNZ-SHUUEZRQSA-N sedoheptulose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO HSNZZMHEPUFJNZ-SHUUEZRQSA-N 0.000 description 1
229960002855 simvastatin Drugs 0.000 description 1
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000012353 t test Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
238000002525 ultrasonication Methods 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)

AU2003296802A 2002-12-12 2003-12-10 Prevention and treatment of alzheimer's disease Abandoned AU2003296802A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR0215722		2002-12-12
FR0215722A FR2848452B1 (fr)	2002-12-12	2002-12-12	Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
PCT/FR2003/003654 WO2004062652A1 (fr)	2002-12-12	2003-12-10	Application et traitement de la maladie d'alzheimer

Publications (1)

Publication Number	Publication Date
AU2003296802A1 true AU2003296802A1 (en)	2004-08-10

Family

ID=32338722

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2003296802A Abandoned AU2003296802A1 (en)	2002-12-12	2003-12-10	Prevention and treatment of alzheimer's disease

Country Status (22)

Country	Link
EP (1)	EP1572174A1 (ja)
JP (1)	JP2006514063A (ja)
KR (1)	KR20050084250A (ja)
CN (1)	CN1726016A (ja)
AR (1)	AR042354A1 (ja)
AU (1)	AU2003296802A1 (ja)
BR (1)	BR0317280A (ja)
CA (1)	CA2507945A1 (ja)
CO (1)	CO5700712A2 (ja)
FR (1)	FR2848452B1 (ja)
HR (1)	HRP20050534A2 (ja)
MA (1)	MA27500A1 (ja)
MX (1)	MXPA05005556A (ja)
NO (1)	NO20053341L (ja)
NZ (1)	NZ540496A (ja)
PE (1)	PE20040770A1 (ja)
PL (1)	PL377110A1 (ja)
RS (1)	RS20050420A (ja)
RU (1)	RU2005121909A (ja)
TW (1)	TW200503707A (ja)
WO (1)	WO2004062652A1 (ja)
ZA (1)	ZA200504656B (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7521481B2 (en)	2003-02-27	2009-04-21	Mclaurin Joanne	Methods of preventing, treating and diagnosing disorders of protein aggregation
NZ546887A (en)	2003-11-03	2009-04-30	Probiodrug Ag	Combinations useful for the treatment of neuronal disorders
JP4996926B2 (ja)	2004-02-05	2012-08-08	プロビオドルグエージー	グルタミニルシクラーゼの新規の阻害剤
WO2006050359A2 (en)	2004-11-02	2006-05-11	Northwestern University	Pyridazine compounds and methods
CA2650711A1 (en)	2006-04-28	2007-11-08	Northwestern University	Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
PL2157973T3 (pl) *	2007-05-22	2015-12-31	Otsuka Pharma Co Ltd	Lek zawierający pochodną karbostyrylu i donepezil do leczenia choroby Alzheimera
MX363161B (es) *	2011-10-28	2019-03-13	Lumena Pharmaceuticals Inc	Inhibidores de la recirculación de ácidos biliares para el tratamiento de hipercolemia y enfermedad hepática colestásica.
US20140243281A1 (en) *	2011-10-28	2014-08-28	Lumena Pharmaceuticals, Inc.	Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2040996A1 (en) *	1990-05-02	1991-11-03	Robert L. Albright	Composition and method for controlling cholesterol
CA2104594C (en) *	1991-02-22	2004-05-11	Howard K. Shapiro	Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
JP2001508762A (ja) *	1996-06-27	2001-07-03	ジー．ディー．サールアンドカンパニー	架橋した外殻領域および内部芯領域を有する両親媒性コポリマーからなり、医薬およびその他の用途に有用な粒子
US5985936A (en) *	1997-12-18	1999-11-16	Forbes Medi-Tech, Inc.	Method of preventing and delaying onset of Alzheimer's disease and composition therefor
ES2257824T3 (es) *	1998-01-28	2006-08-01	Warner-Lambert Company Llc	Metodo para tratar la enfermedad de alzheimer.
US6080778A (en) *	1998-03-23	2000-06-27	Children's Medical Center Corporation	Methods for decreasing beta amyloid protein
DE19825804C2 (de) *	1998-06-10	2000-08-24	Aventis Pharma Gmbh	1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US6221897B1 (en) *	1998-06-10	2001-04-24	Aventis Pharma Deutschland Gmbh	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) *	1998-10-02	2000-07-13	Aventis Pharma Gmbh	Arylsubstituierte Propanolaminderivate und deren Verwendung
WO2001056579A1 (en) *	2000-02-04	2001-08-09	Esperion Therapeutics Inc.	Methods for treating alzheimer's disease
US20020028826A1 (en) *	2000-06-15	2002-03-07	Robl Jeffrey A.	HMG-CoA reductase inhibitors and method
SE0104334D0 (sv) *	2001-12-19	2001-12-19	Astrazeneca Ab	Therapeutic agents
TWI329111B (en) *	2002-05-24	2010-08-21	X Ceptor Therapeutics Inc	Azepinoindole and pyridoindole derivatives as pharmaceutical agents

2002
- 2002-12-12 FR FR0215722A patent/FR2848452B1/fr not_active Expired - Fee Related
2003
- 2003-12-10 KR KR1020057010595A patent/KR20050084250A/ko not_active Application Discontinuation
- 2003-12-10 AU AU2003296802A patent/AU2003296802A1/en not_active Abandoned
- 2003-12-10 PE PE2003001247A patent/PE20040770A1/es not_active Application Discontinuation
- 2003-12-10 RS YUP-2005/0420A patent/RS20050420A/sr unknown
- 2003-12-10 WO PCT/FR2003/003654 patent/WO2004062652A1/fr active Application Filing
- 2003-12-10 MX MXPA05005556A patent/MXPA05005556A/es not_active Application Discontinuation
- 2003-12-10 PL PL377110A patent/PL377110A1/pl not_active Application Discontinuation
- 2003-12-10 CA CA002507945A patent/CA2507945A1/fr not_active Abandoned
- 2003-12-10 AR ARP030104540A patent/AR042354A1/es not_active Application Discontinuation
- 2003-12-10 EP EP03815109A patent/EP1572174A1/fr not_active Withdrawn
- 2003-12-10 NZ NZ540496A patent/NZ540496A/en unknown
- 2003-12-10 RU RU2005121909/15A patent/RU2005121909A/ru not_active Application Discontinuation
- 2003-12-10 CN CNA2003801059727A patent/CN1726016A/zh active Pending
- 2003-12-10 JP JP2004566119A patent/JP2006514063A/ja not_active Abandoned
- 2003-12-10 BR BR0317280-5A patent/BR0317280A/pt not_active IP Right Cessation
- 2003-12-11 TW TW092134949A patent/TW200503707A/zh unknown
2005
- 2005-06-07 ZA ZA200504656A patent/ZA200504656B/en unknown
- 2005-06-09 CO CO05056010A patent/CO5700712A2/es not_active Application Discontinuation
- 2005-06-10 HR HR20050534A patent/HRP20050534A2/xx not_active Application Discontinuation
- 2005-06-10 MA MA28329A patent/MA27500A1/fr unknown
- 2005-07-08 NO NO20053341A patent/NO20053341L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
RS20050420A (en)	2007-04-10
PE20040770A1 (es)	2004-12-10
HRP20050534A2 (en)	2006-11-30
FR2848452A1 (fr)	2004-06-18
CO5700712A2 (es)	2006-11-30
BR0317280A (pt)	2005-11-08
CA2507945A1 (fr)	2004-07-29
NO20053341D0 (no)	2005-07-08
MA27500A1 (fr)	2005-08-01
AR042354A1 (es)	2005-06-15
NO20053341L (no)	2005-09-07
MXPA05005556A (es)	2005-07-26
JP2006514063A (ja)	2006-04-27
NZ540496A (en)	2008-04-30
FR2848452B1 (fr)	2007-04-06
RU2005121909A (ru)	2006-01-20
PL377110A1 (pl)	2006-01-23
ZA200504656B (en)	2006-08-30
WO2004062652A1 (fr)	2004-07-29
TW200503707A (en)	2005-02-01
CN1726016A (zh)	2006-01-25
KR20050084250A (ko)	2005-08-26
EP1572174A1 (fr)	2005-09-14

Legal Events

Date	Code	Title	Description
2009-07-09	MK4	Application lapsed section 142(2)(d) - no continuation fee paid for the application

Publication	Publication Date	Title
CA2301725C (en)	2008-11-18	Specific saccharide compositions and methods for treating alzheimer's disease and other amyloidoses
ES2285772T3 (es)	2007-11-16	Composicion y metodos para tratar la enfermedad de alzheimer y otras amiloidosis.
AU2016222315B2 (en)	2022-08-04	Compositions of selenoorganic compounds and methods of use thereof
US8029831B2 (en)	2011-10-04	Formulations containing thymoquinone for urinary health
JP4909984B2 (ja)	2012-04-04	リグナン系化合物の新規な用途
CN109640967B (zh)	2022-04-29	抑制胆碱向三甲胺(tma)的转化的方法
ZA200504656B (en)	2006-08-30	Prevention and treatment of Alzheimer's disease
KR101639864B1 (ko)	2016-07-14	Bace1 단백질 발현을 감소 조절하는 화합물을 포함하는 퇴행성 뇌질환 예방 또는 치료용 조성물
JP5302900B2 (ja)	2013-10-02	脂肪性肝疾患の治療用医薬組成物
US20180008665A1 (en)	2018-01-11	Methods of treating and preventing gout and lead nephropathy
US20240173341A1 (en)	2024-05-30	Composition for ameliorating or treating dementia containing 2'-fucosyllactose
JP6272646B2 (ja)	2018-02-07	ａｘｉａｌ−ｅｑｕａｔｏｒｉａｌａｒｙｌ配向のｆｕｒｏｆｕｒａｎ型リグナンを含有する骨形成促進用医薬組成物、その組成物を含有する医薬製剤、その組成物を含む機能性食品及び健康食品
KR20160115889A (ko)	2016-10-06	희첨 추출물을 포함하는 골다공증 예방, 개선 또는 치료용 조성물
KR101308144B1 (ko)	2013-09-12	아젤라신 ｄ를 유효성분으로 함유하는 골질환 예방 또는 치료용 약학적 조성물
US20040138145A1 (en)	2004-07-15	Application of intestinal biliary acid reuptake inhibitors for the prevention and treatment of alzheimer's disease
US11376233B2 (en)	2022-07-05	Composition, containing sarpogrelate as active ingredient, for preventing or treating sensorineural hearing loss
JP6664956B2 (ja)	2020-03-13	筋分化促進組成物
TWI833874B (zh)	2024-03-01	神經變性疾病之預防或治療藥
JP7224303B2 (ja)	2023-02-17	薬剤、組成物、及びそれに関連する方法
WO2013049523A1 (en)	2013-04-04	Methods for reducing a-beta-1-42 levels, methods for reducing or preventing formation of amyloid plaques, and methods for improving cognitive function and memory retention in a subject
KR102389889B1 (ko)	2022-04-25	2'-fl을 함유하는 근위축 또는 근감소증 개선, 예방 또는 치료용 조성물
WO2005055997A1 (ja)	2005-06-23	炎症性疾患の治療及び予防用医薬組成物
JP4828135B2 (ja)	2011-11-30	コレステロールの脂質ミセルへの取込抑制剤
WO2007116458A1 (ja)	2007-10-18	神経変性疾患治療薬
JP2011116714A (ja)	2011-06-16	α−アミラーゼ阻害剤